Luciferase Reporter Cell Line - HGC-27

HGC-27 is a human gastric carcinoma cell line widely used as an in vitro model for studying gastric cancer biology, tumor progression, drug response, and molecular signaling associated with malignant epithelial cells of the stomach. The cell line is known for its tumor-derived origin and cancer-related phenotypes, making it suitable for investigations into proliferation, survival, migration, invasion, epithelial–mesenchymal transition, and therapeutic sensitivity in gastric cancer research. Luciferase Reporter Cell Line - HGC-27 is an engineered derivative of the parental HGC-27 cell line that has been modified to stably express a luciferase reporter gene. Because the luciferase gene is integrated and maintained in the cell population, the cells can generate a reproducible bioluminescent signal after addition of the appropriate luciferase substrate. This stable reporter system provides a convenient, sensitive, and quantitative readout of viable tumor cell burden and cellular activity.

The HGC-27 luciferase reporter cell line is applicable to a wide range of cancer research and drug development processes. In in vitro studies, it facilitates high-throughput or medium-throughput screening of anti-cancer compounds, targeted inhibitors, natural products, biologics, immune-related factors, and combination therapies. Researchers can treat these cells with candidate drugs and assess the inhibitory effects of the drugs on cell proliferation or viability by quantitatively measuring luciferase signals. This system is also suitable for dose-response analyses, time-course experiments, cytotoxicity assessments, and comparisons of therapeutic efficacy across different treatment groups. In terms of mechanistic studies, HGC-27-Luc cells can be utilized to explore signaling pathways involved in gastric cancer growth, apoptosis, cell cycle regulation, metastasis-related behaviors, and the development of resistance to chemotherapy or targeted therapies.